NASDAQ · Biotechnology

BMEA (BMEA) Stock

$1.22 +0.00% NASDAQ: BMEA Healthcare

Valuation

MetricValue
Price$1.22
Market Cap$88.21M
P/E Ratio-1.20
P/B Ratio2.82
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$2.99
52-Week Low$0.87
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-206.67%
ROA-105.08%
ROCE-270.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.07
Current Ratio5.27

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-42.0M$-84.0M$-126.0M$-144.0M$-81.0M
Net Profit$-42.0M$-82.0M$-117.0M$-138.0M$-62.0M
EPS$-1.74$-2.80$-3.44$-3.83$-1.18
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$186.0M$129.0M$200.0M$80.0M$59.0M
Total Liabilities$7.0M$21.0M$31.0M$28.0M$29.0M
Cash$146.0M$112.0M$177.0M$58.0M$56.0M
Borrowings$3.0M$2.0M$10.0M$9.0M$2.0M

Latest News

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study GlobeNewswire · Jun 5, 2026 Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity GlobeNewswire · Jun 3, 2026 Biomea Fusion to Participate at Upcoming Investor Conferences GlobeNewswire · May 12, 2026 Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights GlobeNewswire · May 11, 2026 Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions GlobeNewswire · May 5, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-35.0M$-62.0M$-97.0M$-120.0M$-70.0M
Investing Cash Flow$-37.0M$26.0M$-6.0M$-1.0M$0
Financing Cash Flow$0$1.0M$2.0M$0$0
Net Cash Flow$84.0M$-34.0M$65.0M$-119.0M$-2.0M
Free Cash Flow$-39.0M$-63.0M$-100.0M$-120.0M$-70.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-66.58%
Quick Ratio4.98
Interest Coverage—
Return 1Y-29.49%
Return 3Y-94.55%
Return 5Y-90.81%

Ownership

Insiders Held7.17%
Institutions Held38.88%
Institutions Float Held41.88%
Institutional HolderSharesReport Date
FMR, LLC8,813,3592026-03-31
Vanguard Capital Management LLC2,597,3002026-03-31
Aisling Capital Management LP2,048,7572026-03-31
Renaissance Technologies, LLC1,312,7982026-03-31
Marshall Wace LLP1,198,5512026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADVMAdverum Biotechnologies, Inc. $4.36 +0.00% -0.66 $96.26M 0.00%
ALXO $1.95 -2.26% -1.04 $261.72M 0.00%
CAMP $3.47 +6.12% -1.70 $73.70M 0.00%
CBUS $1.93 +0.00% -0.50 $87.79M 0.00%
GUTS $0.80 +3.62% -0.40 $57.83M 0.00%

About BMEA

BMEA is led by CEO Michael J. Hitchcock, employs 79 people, headquartered in US, publicly traded since 2021.

BMEA stock trades at $1.22 with a market capitalization of $88.21M. The stock is valued at a price-to-earnings (P/E) ratio of -1.20, price-to-book of 2.82, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.87 and $2.99, and currently trades 59.2% below its 52-week high.

On profitability, BMEA generates a return on equity (ROE) of -206.67%, return on capital employed of -270.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides